Oncostatin M inhibits decidualization of normal human endometrial stromal cells. 2003

Tetsuji Tanaka, and Naohiko Umesaki
Department of Obstetrics and Gynecology, Wakayama Medical University, Japan. tetanaka@wakayama-med.ac.jp

It is well known that oncostatin M binds and activates leukemia inhibitory factor-specific receptors while leukemia inhibitory factor cannot bind oncostatin M-specific receptors. In this study, the differential effects of oncostatin M and leukemia inhibitory factor on cell survival and decidualization of normal human endometrial stromal cells were investigated by using 8-Br-cAMP-induced decidualization assay. Oncostatin M did not affect the viable cell numbers or the prolactin release of unstimulated stromal cells. However, oncostatin M dose-dependently suppressed prolactin releases from 8-Br-cAMP-stimulating stromal cells but enhanced their viable cell numbers. Although oncostatin M significantly enhanced viable cell numbers of 8-Br-cAMP-stimulated stromal cells, it did not affect prolactin secretion from 8-Br-cAMP-induced decidualized cells. Leukemia inhibitory factor significantly enhanced viable cell numbers of 8-Br-cAMP-stimulating cells in a dose-dependent manner as did oncostatin M, while leukemia inhibitory factor did not show any significant suppression of PRL secretion from 8-Br-cAMP-stimulating cells. These results indicate that oncostatin M inhibits the 8-Br-cAMP-induced decidualization process via oncostatin M-specific receptors and that oncostatin M and leukemia inhibitory factor enhance cell survival of 8-Br-cAMP-stimulated prolactin-non-secreting stromal cells mainly via leukemia inhibitory factor receptors. Thus, oncostatin M may autoregulate human endometrial stromal cell survival and decidualization in a paracrine manner.

UI MeSH Term Description Entries
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D004717 Endometrium The mucous membrane lining of the uterine cavity that is hormonally responsive during the MENSTRUAL CYCLE and PREGNANCY. The endometrium undergoes cyclic changes that characterize MENSTRUATION. After successful FERTILIZATION, it serves to sustain the developing embryo. Endometria
D005260 Female Females
D006131 Growth Inhibitors Endogenous or exogenous substances which inhibit the normal growth of human and animal cells or micro-organisms, as distinguished from those affecting plant growth ( Cell Growth Inhibitor,Cell Growth Inhibitors,Growth Inhibitor,Growth Inhibitor, Cell,Growth Inhibitors, Cell,Inhibitor, Cell Growth,Inhibitor, Growth,Inhibitors, Cell Growth,Inhibitors, Growth
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015124 8-Bromo Cyclic Adenosine Monophosphate A long-acting derivative of cyclic AMP. It is an activator of cyclic AMP-dependent protein kinase, but resistant to degradation by cyclic AMP phosphodiesterase. 8-Bromo-cAMP,8-Br Cyclic AMP,8-Bromo Cyclic AMP,8-Bromo Cyclic Adenosine Monophosphate, Monosodium Salt,8-Bromo Cyclic Adenosine Monophosphate, Sodium Salt,8-Bromoadenosine 3',5'-Cyclic Monophosphate,Br Cycl AMP,8 Br Cyclic AMP,8 Bromo Cyclic AMP,8 Bromo Cyclic Adenosine Monophosphate,8 Bromo Cyclic Adenosine Monophosphate, Monosodium Salt,8 Bromo Cyclic Adenosine Monophosphate, Sodium Salt,8 Bromo cAMP,8 Bromoadenosine 3',5' Cyclic Monophosphate,AMP, Br Cycl,Cyclic AMP, 8-Br,Cyclic AMP, 8-Bromo
D015850 Interleukin-6 A cytokine that stimulates the growth and differentiation of B-LYMPHOCYTES and is also a growth factor for HYBRIDOMAS and plasmacytomas. It is produced by many different cells including T-LYMPHOCYTES; MONOCYTES; and FIBROBLASTS. Hepatocyte-Stimulating Factor,Hybridoma Growth Factor,IL-6,MGI-2,Myeloid Differentiation-Inducing Protein,Plasmacytoma Growth Factor,B Cell Stimulatory Factor-2,B-Cell Differentiation Factor,B-Cell Differentiation Factor-2,B-Cell Stimulatory Factor 2,B-Cell Stimulatory Factor-2,BSF-2,Differentiation Factor, B-Cell,Differentiation Factor-2, B-Cell,IFN-beta 2,IL6,Interferon beta-2,B Cell Differentiation Factor,B Cell Differentiation Factor 2,B Cell Stimulatory Factor 2,Differentiation Factor 2, B Cell,Differentiation Factor, B Cell,Differentiation-Inducing Protein, Myeloid,Growth Factor, Hybridoma,Growth Factor, Plasmacytoma,Hepatocyte Stimulating Factor,Interferon beta 2,Interleukin 6,Myeloid Differentiation Inducing Protein,beta-2, Interferon

Related Publications

Tetsuji Tanaka, and Naohiko Umesaki
December 2017, Experimental and therapeutic medicine,
Tetsuji Tanaka, and Naohiko Umesaki
December 1991, The Journal of clinical endocrinology and metabolism,
Tetsuji Tanaka, and Naohiko Umesaki
September 1994, Annals of the New York Academy of Sciences,
Tetsuji Tanaka, and Naohiko Umesaki
January 2020, Frontiers in cell and developmental biology,
Tetsuji Tanaka, and Naohiko Umesaki
May 1992, The Journal of steroid biochemistry and molecular biology,
Tetsuji Tanaka, and Naohiko Umesaki
April 2020, Reproduction (Cambridge, England),
Tetsuji Tanaka, and Naohiko Umesaki
December 1994, Human reproduction (Oxford, England),
Tetsuji Tanaka, and Naohiko Umesaki
February 2024, Reproductive sciences (Thousand Oaks, Calif.),
Tetsuji Tanaka, and Naohiko Umesaki
March 2017, Reproductive biology and endocrinology : RB&E,
Copied contents to your clipboard!